Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tanimilast - Chiesi Farmaceutici

Drug Profile

Tanimilast - Chiesi Farmaceutici

Alternative Names: CHF 6001 NEXThaler DPI; CHF 6001 NEXThaler®; CHF-6001; CHF6001 DPI

Latest Information Update: 28 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Developer Chiesi Farmaceutici; Chiesi USA
  • Class Antiallergics; Antiasthmatics; Benzoates; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Phenyl ethers; Pyridines; Small molecules; Sulfonamides
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease
  • Phase II Allergic asthma; Asthma

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in United Kingdom (IV, Infusion)
  • 28 Mar 2024 Chiesi Farmaceutici initiates a phase I trial for Chronic obstructive pulmonary disease (In volunteers) in Bulgaria (Inhalation) (NCT06395610)
  • 09 Sep 2023 Pharmacodynamics data from preclinical studies in Chronic obstructive pulmonary disorder presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top